United Therapeutics Corporation
About United Therapeutics Corporation
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation, with many products focused on lung treatments. Founded in 1996 by Martine Rothblatt as a public benefit corporation, it has six FDA-approved therapies for pulmonary arterial hypertension (PAH), PH-ILD, and neuroblastoma. The company is publicly traded on Nasdaq as UTHR with co-headquarters in Silver Spring, Maryland and Research Triangle Park, North Carolina, reporting US$3.18 billion in revenue for 2025.
- 🔗 United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
- 🔗 United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization | Nasdaq
- 🔗 United Therapeutics - Wikipedia
- 🔗 United Therapeutics Investor Relations
- 🔗 United Therapeutics Corporation Employee Directory, Headcount & Staff | LeadIQ
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Founded in 1996 by Martine Rothblatt to develop treatments for pulmonary arterial hypertension.
- First publicly traded biotech or pharmaceutical company structured as a public benefit corporation.
- Holds six FDA-approved therapies targeting PAH, PH-ILD, and neuroblastoma.
- Authorized a new $2 billion share repurchase program available through October 2027.
- Reported US$3.18 billion in revenue for 2025 with co-headquarters in Maryland and North Carolina.
Ask StreetZero about United Therapeutics Corporation
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account